PITPNM3 and prostate adenocarcinoma: Survival analysis (Figure 3H) showed that PRAD patients with high expression of ZNF330, PITPNM3 had lower overall survival (OS), which suggested that ZNF330, PITPNM3 may be a risk factor for poor prognosis.